Method

The scientific basis of this atlas is Physiological Hazards of Combining Dextromethorphan with Other Substances . Study sources .

PHI

PHI is a provisional hazard rating for a combination with DXM on a 0–10 scale. A higher number means greater hazard. Confidence in the exact rating boundaries is low; clinical validation remains outstanding. The rating applies to the conditions stated in the combination’s description. PHI cannot be used to calculate the probability of a specific complication, a dose or a waiting period. Overlapping PHI ranges prevent reliable ranking of which combination is more hazardous.

Calling a severe outcome almost inevitable requires data on outcome frequency in people under defined, comparable conditions. Warnings, individual poisoning cases and plausible mechanisms are considered against this requirement.

PHI color scale

  1. 0
  2. 1–2
  3. 3–4
  4. 5–6
  5. 7–8
  6. 9
  7. 10

Color shows position on the PHI 0–10 scale. Exact numbers and range endpoints are given alongside it. Unrated combinations have their own status.

PHIInterpretation in this review
0Demonstrated absence of a substantial additional hazard under specified conditions; not assigned to any combination
1–2Small expected additional physiological hazard; evidence of safety may still be absent
3–4Meaningful amplification of adverse effects or functional impairment; serious consequences are possible under unfavorable conditions
5–6Substantial interaction with a plausible risk of a clinically significant complication
7–8High concern because of multiple mechanisms or the potential for severe poisoning
9Highest concern and strong grounds to avoid the combination, including contraindications or a closely relevant mechanism of severe toxicity
10Reserved for evidence of an almost inevitable catastrophic outcome under defined conditions; not assigned

Ranges reflect heterogeneous conditions and uncertainty in the assessment. They are not confidence intervals. Adjacent scores express a qualitative difference in judgments. They cannot be used to calculate a risk ratio. The index considers the physiological hazards of the whole combination while identifying the contribution of the interaction. The second substance’s own toxicity and its interaction with DXM are described as different components of hazard.

Confidence in the exact numerical boundaries of all ratings is Low; mechanism confidence cannot validate an ordinal score.

Scientific review: 3. The index and its limitations

How well is this understood?

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

For some explanations, the type of evidence has not been classified. Their links lead to the review.

AUC is the area under the graph of blood concentration over time. Cmax is the highest measured concentration. DXO is dextrorphan, an active product of DXM breakdown. These measures describe drug concentration and metabolism.

Scientific review: 2. Sources and methods

Symbols beside the confidence assessment

Measurements of drug concentration or metabolism.Overdose data; they do not show outcome frequency at ordinary exposures.The study did not find the effect it tested for.

Scientific review: 2. Sources and methods

Rating conditions

Scientific review: 1. Scope and assumptions

What limits this finding?

The site draws on studies, clinical reports and medicine prescribing information. Some sources were available only as abstracts. A finding needs to be read together with what was measured and the study conditions.

The historical section pairs older FAQ statements with current commentary. Sources and conditions for current conclusions appear beside the relevant text.

Scientific review: 9. Exclusions, repeated use, and limits of extrapolation

Terms

Reuptake

Return of a released neurotransmitter into a cell through a transporter protein.

Allows neurotransmitter recycling.

Sources: Reuptake

Neurotransmitter release

Movement of neurotransmitter molecules from a nerve ending into the space between cells.

During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.

Sources: Neurotransmitter release

Enzyme

A protein that helps chemical transformations in cells.

A transformation can build or break down a substance.

Sources: Enzyme

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

NMDA receptor

A glutamate receptor that controls an ion channel in a cell.

An ion channel lets electrically charged particles pass.

Sources: NMDA receptor

GABA

A neurotransmitter associated with inhibiting nerve-cell activity.

GABA-A and GABA-B are different receptor types.

Sources: GABA

CYP

A family of enzymes involved in chemically transforming drugs.

Metabolism can reduce or increase a substance’s activity.

Sources: CYP

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6

Receptor

A protein that binds particular molecules and participates in a cell response.

Different receptors have different functions.

Sources: Receptor

SERT

A transporter protein involved in serotonin reuptake.

Inhibiting transport differs from acting on receptors.

Sources: SERT

KOR — κ-opioid receptor

One type of opioid receptor.

κ and μ are labels for different types of opioid receptor.

Sources: KOR — κ-opioid receptor

Pharmacokinetics (PK)

Study of how the body absorbs, distributes and eliminates a substance.

This includes concentration changes over time.

Sources: Pharmacokinetics (PK)

Metabolite

A substance formed when another substance is chemically transformed in the body.

Some transformation products retain pharmacological activity.

Sources: Metabolite

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

Neurotransmitter

A substance that a nerve cell releases to send a chemical signal to another cell.

Receptors on the receiving cell respond to the signal. This is one way nerve cells communicate.

Sources: Neurotransmitter

Serotonin

A neurotransmitter: a substance that carries a chemical signal from a nerve cell.

There are different serotonin receptors in the brain and other parts of the body. The response to the signal depends on the receptor and its location.

Sources: Serotonin

MAO-A

A form of the MAO enzyme involved in breaking down some chemical messengers, including serotonin.

These messengers are monoamines. MAO-A and MAO-B are two different forms of monoamine oxidase.

Sources: MAO-A

MAO-B

A form of the MAO enzyme involved in breaking down some chemical messengers in the monoamine group.

MAO-A and MAO-B are two different forms of monoamine oxidase. The letter B identifies the enzyme form.

Sources: MAO-B

CYP3A

A group of related CYP enzymes involved in the chemical transformation of medicines.

CYP3A is an enzyme group that includes CYP3A4 and CYP3A5.

Sources: CYP3A

QT interval

The time interval between the Q and T waves on an ECG recording of the heart’s electrical activity.

It reflects the electrical activity of the ventricles, the heart’s lower chambers.

Sources: QT interval

Drug metabolism

Chemical transformation of a medicine in the body.

The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.

Sources: Drug metabolism

Metabolic activation

Transformation of an inactive precursor into an active drug in the body.

Further explanation

Activation here describes the substance produced by metabolism.

Sources: Metabolic activation

AUC

Area under the graph of a drug’s plasma concentration over time.

It combines concentration and time to describe drug exposure over an interval.

Sources: AUC

Cmax

The highest drug concentration in plasma on a concentration–time curve.

It describes the peak concentration. AUC describes the area under the curve.

Sources: Cmax

Drug exposure

Description of how much of a medicine is present in the body, using its concentrations.

Cmax describes the concentration peak; AUC combines concentrations over time.

Sources: Drug exposure

Opioid

A drug that acts by binding to opioid receptors.

These receptors are found in the nervous system and other organs.

Sources: Opioid

Sedation

A drug-induced state of calmness, relaxation or sleepiness.

Sources: Sedation

Hypoxia

Reduced oxygen supply to a tissue.

Sources: Hypoxia

Antimuscarinic action

Blocking the action of acetylcholine at muscarinic receptors.

Muscarinic receptors are one type of receptor for acetylcholine, a chemical messenger.

Sources: Antimuscarinic action

Adrenergic signaling

Signaling in which noradrenaline or adrenaline acts on adrenergic receptors.

The response depends on the receptor type and its location.

Sources: Adrenergic signaling

GABA-A receptor

A receptor for GABA that forms an ion channel in the cell membrane.

It differs from the GABA-B receptor, which signals through a G protein.

Sources: GABA-A receptor

GABA-B receptor

A receptor for GABA that signals through a G protein inside the cell.

It differs from the GABA-A receptor, which forms an ion channel.

Sources: GABA-B receptor

Ischemia

Insufficient blood supply to part of the body.

A lack of oxygen and nutrients can damage the tissue.

Sources: Ischemia

Arrhythmia

A disturbance of the heart’s rate or rhythm.

The heart can beat too fast, too slowly or irregularly.

Sources: Arrhythmia

Vitamin B12

A vitamin that helps keep blood and nerve cells healthy.

It also helps make DNA, the cells’ genetic material.

Sources: Vitamin B12

Monoamines

A group of substances formed in living organisms; several act as chemical messengers between nerve cells.

Examples include serotonin, dopamine and norepinephrine.

Sources: Monoamines

Catecholamines

A group of chemical messengers made by nerve cells.

Examples are dopamine, adrenaline and noradrenaline.

Sources: Catecholamines

Pharmacodynamics

The study of a drug’s effects on the body.

This includes its beneficial and harmful effects.

Sources: Pharmacodynamics

Dissociation

A sense of disconnection between thoughts, memory and one’s sense of self.

One form involves feeling detached from the surrounding people, places or objects.

Sources: Dissociation

Airway protective reflexes

Reflex actions that help protect the airways.

Coughing and swallowing are examples; they work in a coordinated way.

Sources: Airway protective reflexes

Hepatotoxicity

Liver injury caused by a toxic substance.

Possible sources include medicines, chemicals, herbal products and dietary supplements.

Sources: Hepatotoxicity

Systemic effects

Effects occurring away from the place where a substance enters the body.

The substance is absorbed and distributed through the body.

Sources: Systemic effects

Neuroprotection

Processes that help prevent injury and degeneration of nerve cells in the central nervous system.

Further explanation

The name describes protection of nerve cells.

Sources: Neuroprotection

Olney’s lesions (rat experiments)

Changes in nerve cells of the brain’s cortex described in adult-rat experiments involving NMDA receptor blockade.

Small cavities, called vacuoles, appear within the cells; these changes can be reversible.

Sources: Olney’s lesions (rat experiments)

Extrapolation

Using information from studied groups, conditions or products to draw conclusions about other groups, conditions or products.

This relies on assumptions about how the studied and new situations are related.

Sources: Extrapolation

Demethylation

A chemical change that removes one or more methyl groups from a compound.

A methyl group contains one carbon atom and three hydrogen atoms.

Sources: Demethylation

Recovery half-life

A measure of how quickly enzyme activity recovers, calculated from changes in an activity marker over time.

In an exponential model, the recovery half-life is the time for a falling marker to halve. The marker can be the ratio of a test substance to its breakdown product.

Sources: Recovery half-life

Serotonin toxicity

A condition caused by excessive serotonin activity in the nervous system.

Also called serotonin syndrome. Features can include tremor and involuntary muscle jerks, raised body temperature, a fast heartbeat, agitation or confusion.

Sources: Serotonin toxicity

Additive effects

A combined effect that matches the expected addition of the substances’ actions.

This is called additivity. The expected result is calculated from each substance’s action on its own, using the same measured effect and a chosen model of addition.

Sources: Additive effects

Synergy

A combined effect that is stronger than expected from additivity.

Synergy is assessed by comparing the measured combined effect with the result predicted from the substances’ separate actions. The comparison uses a specified effect and a chosen model of additivity.

Sources: Synergy

MAO-B selectivity

Preferential inhibition of the MAO-B form of the enzyme compared with MAO-A.

MAO-A and MAO-B are two forms of monoamine oxidase. Loss of selectivity means more pronounced inhibition of MAO-A.

Sources: MAO-B selectivity

Sympathomimetic decongestants

Medicines that relieve a blocked nose by narrowing blood vessels in its lining.

They mimic effects of the sympathetic nervous system. Narrowing these vessels reduces swelling of the nasal lining and helps air pass through.

Sources: Sympathomimetic decongestants

Alkaloids

A group of nitrogen-containing substances found in plants and some fungi.

Alkaloids are also made in the laboratory. Caffeine and nicotine are examples of this group.

Sources: Alkaloids

Ceiling effect

The greatest response attainable for a particular effect of a substance.

Near this limit, increasing the dose produces progressively smaller gains in the effect. Each measured effect has its own dose–response relationship.

Sources: Ceiling effect

Educational material. Remember that each person's body is unique.

zlnmzgprojects@gmail.com
Reference

Open the source and related combinations →